106 related articles for article (PubMed ID: 38723644)
1. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Miethke AG; Moukarzel A; Porta G; Covarrubias Esquer J; Czubkowski P; Ordonez F; Mosca A; Aqul AA; Squires RH; Sokal E; D'Agostino D; Baumann U; D'Antiga L; Kasi N; Laborde N; Arikan C; Lin CH; Gilmour S; Mittal N; Chiou FK; Horslen SP; Huber WD; Jaecklin T; Nunes T; Lascau A; Longpre L; Mogul DB; Garner W; Vig P; Hupertz VF; Gonzalez-Peralta RP; Ekong U; Hartley J; Laverdure N; Ovchinsky N; Thompson RJ
Lancet Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723644
[TBL] [Abstract][Full Text] [Related]
2. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
Thompson RJ; Arnell H; Artan R; Baumann U; Calvo PL; Czubkowski P; Dalgic B; D'Antiga L; Durmaz Ö; Fischler B; Gonzalès E; Grammatikopoulos T; Gupte G; Hardikar W; Houwen RHJ; Kamath BM; Karpen SJ; Kjems L; Lacaille F; Lachaux A; Lainka E; Mack CL; Mattsson JP; McKiernan P; Özen H; Rajwal SR; Roquelaure B; Shagrani M; Shteyer E; Soufi N; Sturm E; Tessier ME; Verkade HJ; Horn P
Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):830-842. PubMed ID: 35780807
[TBL] [Abstract][Full Text] [Related]
3. Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 study.
Loomes KM; Squires RH; Kelly D; Rajwal S; Soufi N; Lachaux A; Jankowska I; Mack C; Setchell KDR; Karthikeyan P; Kennedy C; Dorenbaum A; Desai NK; Garner W; Jaecklin T; Vig P; Miethke A; Thompson RJ
Hepatol Commun; 2022 Sep; 6(9):2379-2390. PubMed ID: 35507739
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
Gonzales E; Hardikar W; Stormon M; Baker A; Hierro L; Gliwicz D; Lacaille F; Lachaux A; Sturm E; Setchell KDR; Kennedy C; Dorenbaum A; Steinmetz J; Desai NK; Wardle AJ; Garner W; Vig P; Jaecklin T; Sokal EM; Jacquemin E
Lancet; 2021 Oct; 398(10311):1581-1592. PubMed ID: 34755627
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.
Ovchinsky N; Aumar M; Baker A; Baumann U; Bufler P; Cananzi M; Czubkowski P; Durmaz Ö; Fischer R; Indolfi G; Karnsakul WW; Lacaille F; Lee WS; Maggiore G; Rosenthal P; Ruiz M; Sokal E; Sturm E; van der Woerd W; Verkade HJ; Wehrman A; Clemson C; Yu Q; Ni Q; Ruvido J; Manganaro S; Mattsson JP
Lancet Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38670135
[TBL] [Abstract][Full Text] [Related]
6. Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency.
Zhao X; Zhang W; Vig P; Kostrub C; Setchell KDR
Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295854
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series.
Masahata K; Ueno T; Bessho K; Kodama T; Tsukada R; Saka R; Tazuke Y; Miyagawa S; Okuyama H
Surg Case Rep; 2022 Jan; 8(1):10. PubMed ID: 35024979
[TBL] [Abstract][Full Text] [Related]
8. Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome.
Shneider BL; Spino C; Kamath BM; Magee JC; Bass LM; Setchell KD; Miethke A; Molleston JP; Mack CL; Squires RH; Murray KF; Loomes KM; Rosenthal P; Karpen SJ; Leung DH; Guthery SL; Thomas D; Sherker AH; Sokol RJ;
Hepatol Commun; 2018 Oct; 2(10):1184-1198. PubMed ID: 30288474
[TBL] [Abstract][Full Text] [Related]
9. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
12. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
13. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
[TBL] [Abstract][Full Text] [Related]
15. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.
Goel G; King T; Daveson AJ; Andrews JM; Krishnarajah J; Krause R; Brown GJE; Fogel R; Barish CF; Epstein R; Kinney TP; Miner PB; Tye-Din JA; Girardin A; Taavela J; Popp A; Sidney J; Mäki M; Goldstein KE; Griffin PH; Wang S; Dzuris JL; Williams LJ; Sette A; Xavier RJ; Sollid LM; Jabri B; Anderson RP
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):479-493. PubMed ID: 28506538
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials.
Hof WFJ; de Boer JF; Verkade HJ
Expert Opin Emerg Drugs; 2024 Apr; ():. PubMed ID: 38571480
[TBL] [Abstract][Full Text] [Related]
17. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis.
Thompson RJ; Artan R; Baumann U; Calvo PL; Czubkowski P; Dalgic B; D'Antiga L; Di Giorgio A; Durmaz Ö; Gonzalès E; Grammatikopoulos T; Gupte G; Hardikar W; Houwen RHJ; Kamath BM; Karpen SJ; Lacaille F; Lachaux A; Lainka E; Loomes KM; Mack CL; Mattsson JP; McKiernan P; Ni Q; Özen H; Rajwal SR; Roquelaure B; Shteyer E; Sokal E; Sokol RJ; Soufi N; Sturm E; Tessier ME; van der Woerd WL; Verkade HJ; Vittorio JM; Wallefors T; Warholic N; Yu Q; Horn P; Kjems L
JHEP Rep; 2023 Aug; 5(8):100782. PubMed ID: 37456676
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis.
Kubitz R; Dröge C; Kluge S; Stross C; Walter N; Keitel V; Häussinger D; Stindt J
Clin Rev Allergy Immunol; 2015 Jun; 48(2-3):273-84. PubMed ID: 25342496
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.
Mayo MJ; Pockros PJ; Jones D; Bowlus CL; Levy C; Patanwala I; Bacon B; Luketic V; Vuppalanchi R; Medendorp S; Dorenbaum A; Kennedy C; Novak P; Gu J; Apostol G; Hirschfield GM
Hepatol Commun; 2019 Mar; 3(3):365-381. PubMed ID: 30859149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
